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Abstract
Growing evidence indicates that intracellular signaling mediat-
ed by extracellular vesicles (EVs) released by stem cells plays a
considerable role in triggering the regenerative program upon
transplantation. EVs from umbilical cord mesenchymal stem
cells (UC-MSC-EVs) have been shown to enhance tissue repair
in animal models. However, translating such results into clinical
practice requires optimized EV collection procedures devoid of
animal-originating agents. Thus, in this study, we analyzed the
influence of xeno-free expansionmedia on biological properties
of UC-MSCs and UC-MSC-EVs for future applications in car-
diac repair in humans. Our results show that proliferation, dif-
ferentiation, phenotype stability, and cytokine secretion by UC-
MSCs vary depending on the type of xeno-free media.
Importantly, we found distinct molecular and functional prop-
erties of xeno-free UC-MSC-EVs including enhanced
cardiomyogenic and angiogenic potential impacting on target
cells, which may be explained by elevated concentration of
several pro-cardiogenic and pro-angiogenic microRNA
(miRNAs) present in the EVs. Our data also suggest predomi-
nantly low immunogenic capacity of certain xeno-free UC-
MSC-EVs reflected by their inhibitory effect on proliferation
of immune cells in vitro. Summarizing, conscious selection of
cell culture conditions is required to harvest UC-MSC-EVs
with the optimal desired properties including enhanced cardiac
and angiogenic capacity, suitable for tissue regeneration.
Key message
& Type of xeno-free media influences biological properties
of UC-MSCs in vitro.
& Certain xeno-free media promote proliferation and differ-
entiation ability of UC-MSCs.
& EVs collected from xeno-free cultures of UC-MSCs are
biologically active.
& Xeno-free UC-MSC-EVs enhance cardiac and angiogenic
potential of target cells.
& Type of xeno-free media determines immunomodulatory
effects mediated by UC-MSC-EVs.
Keywords Extracellular vesicles .Mesenchymal stem cells .
Umbilical cord . Xeno-free . Immunomodulation . Heart
regeneration
Introduction
The therapeutic potential of mesenchymal stem cells (MSCs)
not only has been widely studied in animal models [1] but was
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also validated for human patients, indicating efficacy in the
treatment of a variety of diseases [2, 3]. Among different pop-
ulations of MSCs isolated from various sources, umbilical
cord-derived MSC (UC-MSCs) are particularly promising,
due to their high proliferative potential, longevity, immuno-
modulatory properties, and noninvasive isolation procedure
[4]. Interestingly, although the beneficial effects of stem cell-
based therapy have been widely appreciated, the level of
engrafted cells was usually very low suggesting that the para-
crine activity of stem cells rather than direct differentiation
plays a key role in tissue repair [5]. Among paracrine factors,
circular cell-membrane enclosed cytoplasmic structures
termed extracellular vesicles (EVs) have been recognized as
important mediators of cell-to-cell communication [6]. It was
shown that EVs can interact with cell surface receptors or fuse
with a cell membrane and transfer bioactive cargo in the form
of messenger RNA (mRNA), microRNA (miRNA), proteins,
and lipids to the recipient cells, triggering specific intracellular
signaling pathways, thereby influencing cell fate [6, 7].
Importantly, compelling evidence supports the significance
of EV-mediated signaling in a variety of physiological and
pathological processes, including embryonic development,
the maintenance of tissue homeostasis [8], spread of patho-
gens or modulating disease onset, and progression [9].
Prominently, EVs derived from human mesenchymal stem
cells (MCS-EVs) were shown to enhance regeneration of var-
ious tissues in animal models [10–16], thus creating a new
treatment option for many disorders. In particular, such thera-
py could be used to improve regeneration of the infarcted or
diseased heart, conditions which are the leading causes of
morbidity and mortality worldwide [17], despite the available
modalities. To prove this theory, there are reports showing that
MSC-EVs infusion to the experimental animals ameliorated
myocardial ischemia/reperfusion injury [14] and markedly en-
hanced blood flow recovery accompanied by reduction of the
infarct size of the heart [15]. However, to fully translate the
beneficial effects of MSC-EVs treatment into the clinic, there
is a need to carefully define and standardize cell culture con-
ditions for EVs collection, devoid of any substrates of animal
origin.
Various chemically defined xeno-free media dedicated to
support MSCs growth and characteristics have been offered
on the market and their ability to maintain MSCs properties
has already been confirmed [18–21]. However, the impact of
such media on the therapeutic properties of MSCs and MSC-
derived EVs has never been studied. Since MSC-EVs may be
an attractive cell substitute in future clinical applications, in
this study, we provide, for the first time, a comprehensive
analysis of the biological activities of UC-MSCs and their
acellular derivatives such as EVs in five different xeno-free
media, compared to a standard serum-based medium and a
serum-reduced medium supplemented with basic fibroblast
growth factor (bFGF). Our goal was to identify the most
optimal serum-free and xeno-free cell culture conditions for
collection of therapeutically valuable UC-MSC-EVs for their
potential use in heart regeneration.
Materials and methods
Cell culture
Human UC-MSCs, human umbilical vein endothelial cells
(HUVECs), human cardiac mesenchymal stromal cells
(cMSCs), and human peripheral blood mononuclear cells
(PBMCs) were obtained and maintained under the approval
of local ethical committees.
Umbilical cords were provided by the Polish Stem Cell
Bank accordingly to required approvals and procedures. UC-
MSCs were isolated from five umbilical cords using an ex-
plant method as previously described [22]. Cells were cultured
in DMEM/F12 (Gibco/Thermo Fisher Scientific, Waltham,
MA, USA) supplemented with 10 % fetal bovine serum
(FBS; Sigma-Aldrich, St. Louis, MO, USA) and penicillin/
streptomycin solution (P/S; Gibco) until passages 1–2 and
then they were adapted to serum-free and xeno-free media
by half medium change for 2–3 days. Upon adaptation, for
further experiments, cell passage was assigned as 1. Four
commercially available and one previously published [23]
serum-free and xeno-free media were tested along with a stan-
dard serum-based medium and a serum-reduced medium (5%
FBS) supplemented with 5 ng/mL bFGF (Peprotech, Rocky
Hill, NJ, USA). A full list of media is provided in Table 1.
Cells cultured in all xeno-free media were grown on surfaces
coated with recombinant human fibronectin (Sigma-Aldrich,
no. F1056).
HUVECs were isolated with a method described previous-
ly [24]. Briefly, umbilical vein was washed extensively with
phosphate buffered saline (PBS; GE Healthcare Life Sciences
HyClone Laboratories, South Logan, UT, USA) to remove
blood cells, filled with 1.5 mg/mL collagenase type I solution
(Sigma-Aldrich) and left for 30min at room temperature (RT).
Released cells were collected into a 50-mL tube. Additionally,
the vein was perfused with three volumes of PBS and the cells
were centrifuged at 300×g for 5 min at RT. HUVECs were
cultured in EGM-2MV medium (Lonza, Basel, Switzerland)
on cell culture plates coated with 0.1 % gelatin (Sigma-
Aldrich).
cMSCs were isolated from heart biopsies removed during
operations according to a protocol described previously [25].
cMCSs were cultured in DMEM/F12 (Sigma-Aldrich) con-
taining 15 % FBS (Sigma-Aldrich) and P/S (Gibco).
PBMCs were isolated from peripheral blood of human
healthy donors (n = 5) on Pancol gradient (PAN Biotech;
Aidenbach, Germany). Briefly, whole blood was diluted in
1:1 ratio with PBS, gently added on the top of Pancol and
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centrifuged at 400×g for 30 min at RT. The interface contain-
ing mononuclear cells was collected and washed in five vol-
umes of PBS, then centrifuged at 300× g for 7 min at RT.
PBMCs were cultured in RPMI (Sigma-Aldrich) supplement-
ed with 10 % FBS (Sigma-Aldrich) and P/S (Gibco).
Metabolism assessment
Intracellular ATP concentration was measured with the
ATPlite™ luminescence assay system (PerkinElmer,
Waltham, MA, USA), according to the vendor’s recommen-
dations. Luminescence was measured using the Infinite M200
Microplate Reader (Tecan, San Jose, CA, USA).
Luminex-based quantitative measurement of cytokines
Conditioned media from all culture conditions were collected
after the third passage and stored frozen at −80 °C prior to
analysis. Concentrations of selected cytokines and
chemokines were measured using the Luminex technology-
based BioPlex Pro™ Human Cytokine 17-plex Assay
(BioRad, Berkeley, CA, USA) and the BioPlex®
MAGPIX™ Multiplex Reader (BioRad). First, media were
centrifuged for 15 min at 2000×g to remove cell debris and
then processed according to the manufacturer’s instruction.
The concentrations of the following interleukins: IL-1β, IL-
2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, and
IL-17; interferon (IFN)-γ; monocyte chemoattractant protein
(MCP-1/MCAF); granulocyte colony-stimulating factor (G-
CSF); macrophage colony-stimulating factor (GM-CSF);
macrophage inflammatory protein (MIP-1β); and tumor ne-
crosis factor (TNF)-α were calculated with the Bio-Plex
Manager MP and Bio-Plex Manager 6.1 software (BioRad).
Senescence assay
After the sixth passage in xeno-free and control media, cells
were seeded on glass culture dishes coated with human fibro-
nectin (Sigma-Aldrich) or without coating, respectively, and
cultured for the next 3 days. Senescence assay was performed
using the Senescence β-Galactosidase Staining Kit (Cell
Signaling Technologies, Danvers, MA, USA), according to
the manufacturer’s protocol. The senescence of the cells was
assessed as the percentage of blue (β-galactosidase-positive)
cells.
Isolation of extracellular vesicles
Cell culture supernatants were collected at passages 3–4 from
all tested xeno-free and control media. EVs were isolated
using the sequential centrifugation protocol, as previously de-
scribed [25]. Briefly, supernatants were first centrifuged at
2000×g for 20 min at 4 °C to remove remaining cells, cellular
debris, and apoptotic bodies. Subsequently, cleared superna-
tants were subjected to double ultracentrifugation at
100,000×g for 70 min, at 4 °C, with an intermediate washing
step in PBS. Obtained EVs pellets were resuspended in 150–
200 μL of PBS (Lonza), and protein concentration was deter-
mined with the Bradford assay.
Particle size analysis
The concentration and size distribution of EVs were measured
with tuneable resistive pulse sensing (tRPS) technology using
qNano system (Izon Science Ltd., Oxford, UK). The instru-
ment was set up and calibrated using CPC200 beads (Izon
Science) according to manufacturer’s instructions. EV sam-
ples were diluted 20× in ultrapure PBS (Lonza) and passed
through a 0.45 μmAcrodisc Minispike syringe filters (Sigma-
Aldrich). EVs were measured using a NP200 nanopore (anal-
ysis range 100–400 nm; Izon Science) with 20 or 10 mbar
pressure. Stretch and voltage were set up in order to achieve
a stable higher than 100 nA current. Samples were analyzed
for 5 min or until 1000 vesicles were counted. Data processing
and analysis were carried out on the Izon Control Suite soft-
ware v2.2 (Izon Science).
Table 1 List of cell culture media
used in the study No. Medium name Company Cat. No
M1 MSCGM-CD™ Bullet Kit Lonza 190632
M2 PPRF—msc6—composition based on published
data [23]
Sigma-Aldrich/ Gibco [23]
M3 StemPro® MSC SFM Xenofree Gibco A1067501
M4 MSC NutriStem® XF Basal Medium + MSC





M5 StemXVivo™ R&D Systems CCM014
M6 Control-1: DMEM/F12 + 10 % FBS Sigma-Aldrich D6421; F0804
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Western blot analysis
EV protein extracts (300 μg per medium type) were separated
by Mini-PROTEAN TGXPrecast Gels (BioRad) and trans-
ferred to PVDF membranes by using Trans-Blot Turbo RTA
Mini PVDF Transfer Kit (BioRad). The expression level of
Syntenin and CD63 was evaluated by using goat polyclonal
IgG Syntenin/SDCBP antibody (PA5-18595, Invitrogen/
Thermo Fisher Scientific) and mouse monoclonal IgG
exosome—anti-CD63 antibody (10628D, Invitrogen), respec-
tively. An equal loading in the lanes was evaluated by mouse
monoclonal IgG β-actin antibody (sc-81178, Santa Cruz
Biotechnology). The level of analyzed proteins was subse-
quently detected with horseradish peroxidase (HRP)-conju-
gated rabbit anti-goat IgG (H+L) secondary antibody
(R21459, Invitrogen) or goat anti-mouse IgG, IgM (H+L)
secondary antibody (31,444, Invitrogen). All antibodies were
used according to manufacturer’s protocols. The membranes
were developed with Luminata Crescendo Western HRP
Substrate (Merck/Millipore, Darmstadt, Germany) and im-
aged by Gel Doc XR+Gel Documentation System (Bio-Rad).
Flow cytometry
Surface antigens on UC-MSCs were analyzed after passage 3
in each of the tested media. Cells were harvested with TrypLe
Select Enzyme (Gibco), and the cell suspension was centri-
fuged at 200×g for 5 min. Cells (105) were stained with a
specific fluorescent-conjugated antibody directed toward an-
tigens: CD90, CD166, CD105, CD44, CD73, and HLA-DR
(all PE-labeled from Biolegend, San Diego, CA, USA); CD29
(PE-Cy-5; Biolegend); or CD34, CD45, CD14, and CD16
(FITC labeled from BD Biosciences, San Jose, CA, USA).
The labeling procedure was performed in 100 μL of staining
buffer, composed of PBS containing 2 % FBS, for 30 min at
4 °C in the dark. Next, cells were washed in PBS, resuspended
in 300 μL of staining buffer and were collected using the BD
LSRFortessa flow cytometer (BD Biosciences). Obtained data
were analyzed with FlowJo software (FlowJo, LLC, Ashland,
OR, USA).
Surface markers on UC-MSC-derived EVs were detected
using the Apogee A50-Micro Flow Cytometer (Apogee Flow
Systems, Hemel Hempstead, UK) upon staining with the
SYTO® RNASelect™ Green Fluorescent cell Stain solution
(Molecular Probes/Thermo Fisher Scientific), a highly selec-
tive RNA dye and a subset of antibodies described above with
addition of anti-CD49e antibody (Biolegend). Briefly,
SYTO® RNASelect™ green fluorescent cell stain was diluted
in PBS (Lonza) according to the manufacturer’s protocol and
then centrifuged for 20 min at 21,000×g at 4 °C in order to
remove dye aggregates. EVs suspended in PBS (Lonza) were
incubated with the RNA dye and selected antibodies for
15 min in the dark. The percentage of positive events was
calculated using Apogee Histogram software (Apogee Flow
Systems).
Quantitative real time RT-PCR analysis
For mRNA analysis, total cellular RNAwas isolated using the
GeneMATRIX Universal RNA Purification Kit (Eurx,
Gdansk, Poland) including a DNA digestion step with the
TurboDNAse (Ambion/Thermo Fisher Scientific) and reverse
transcribed with the NG dART RT Kit (Eurx) according to the
manufacturer’s recommendation.
For miRNA analysis, cellular RNA was isolated with the
Total RNA isolation Kit (Exiqon, Vedbaek, Denmark) with
the use of Turbo DNAse (Ambion) and transcribed to com-
plementary DNA (cDNA) with the Universal cDNA
Synthesis Kit II (Exiqon) following the vendor ’s
recommendation.
Transcript levels were measured using the real-time PCR
method with the SYBR Green Master Mix (Applied
Biosystems/Thermo Fisher Scientific) and specific primer sets
(Supplementary Table S1). miRNA expression was analyzed
with custom-designed plates containing the miRNA locked
nucleic acid (LNA)™ primers (Exiqon). Quantification of
mRNA/miRNA content was performed on the 7500Fast
Real-Time PCR System (Applied Biosystems) using the
ΔΔCt method. Gene expression levels were calibrated with
a housekeeping gene—β-2-microglobulin. miRNA content in
EVs was standarized with has-miR-103-3p, identified as a
normalizer by the Norm Finder tool from the GenEx software
(Exiqon).
Cell proliferation
UC-MSCs cultured in five different xeno-free media and two
control media were seeded at passages 1, 3, and 6 on 24-well
plates at 1 × 104 cells/well in duplicate. After 3 days, cells
were harvested with TrypLe Select Enzyme (Gibco) and
counted using a hemocytometer.
Proliferation of cMSCs treated with UC-MSC-EVs was
measured using the Cell Counting Kit-8 (Sigma-Aldrich), ac-
cording to the manufacturer’s instruction. Briefly, cMSCs
were seeded on 96-well plates at 103 cells/well and were treat-
ed with 1 μg of EVs, which corresponded to the EV yield
harvested from approximately 1.2 × 105 cells, for 24 h.
Then, EVs were removed and cells were kept either in hyp-
oxia (1 % O2) or at normal oxygen level (21 % O2) for 4 days.
The absorbance of formazan dye produced by living cells was
measured in an Infinite M200 Microplate Reader (Tecan).
Differentiation assays
UC-MSC cultured in xeno-free and control media were sub-
jected to differentiation into osteocytes, chondrocytes, and
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adipocytes. After the third passage, 3 × 103 cells were seeded
on 12-well plates and were left to grow for the next 2 days
before medium change into differentiation medium.
StemPro® Osteogenesis Differentiation Kit, StemPro®
Adipogenesis Differentiat ion Kit , and StemPro®
Chondrogenesis Differentiation Kit (all from Gibco) were
used for osteogenesis, adipogenesis, and chondrogenesis, re-
spectively. Cells were maintained in differentiation media for
21 days, with medium change every 3–4 days. Next, cells
were fixed and stained with 2 % Alizarin Red (Sigma-
Aldrich) to detect calcium phosphate deposits released by os-
teocytes or were stained with 1 % Alcian Blue solution
(Sigma-Aldrich) in order to indicate synthesis of proteogly-
cans by chondrocytes. Adipogenic differentiation was evalu-
ated by the presence of fat droplets.
Cardiomyocyte differentiation of cMSCs treated with UC-
MSC-EVs was performed using a method described previous-
ly [26]. Briefly, 2 × 104 cMSCs were seeded per well in 12-
well plates coated with 50 μg/mL collagen type I (Sigma-
Aldrich) in DMEM/F12 with 15 % FBS (Sigma-Aldrich).
After 24 h, UC-MSC-EVs collected from approximately
3.6 × 106 cells were added (equivalence of 30 μg EVs/well)
and incubated with cells for 24 h. After washing with PBS, the
medium was changed into differentiation medium, composed
of DMEM/F12 supplemented with 2 % FBS and 10 ng/mL
bFGF, 10 ng/mL VEGF, and 10 ng/mL TGFβ1 (all growth
factors from Peprotech). The medium was changed every day
and after 7 days, cells were examined for cardiac
differentiation.
Immunocytochemistry
cMSCs treated with UC-MSC-EVs and subjected to cardiac
differentiation were examined for expression of cardiac
markers by immunocytochemistry. First, cells were fixed in
4 % paraformaldehyde, permeabilized in 0.2 % Triton X-100,
and blocked with 1 % BSA. Subsequently, cells were incubat-
ed with a mouse monoclonal antibody against human GATA-
4 (G-4) (Santa Cruz Biotechnology, Dallas, TX, USA) and
goat polyclonal antibody against human Troponin T-C
(C-19) (Santa Cruz Biotechnology) in blocking solution, con-
taining autoMACS running buffer (Miltenyi Biotec, Bergisch
Gladbach, Germany), 2 % FBS, and 2 % donkey serum. After
overnight incubation, cells were rinsed and incubated with
secondary antibodies Alexa Fluor 488 AffiniPure F(ab’)
Fragment, donkey anti-mouse IgG (H+L) (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA) and
Alexa Fluor® 546 donkey anti-goat IgG (H+L) (Molecular
Probes) in blocking solution for 2 h. Stained cells were visu-
alized by Leica DMI6000B ver. AF7000 microscope. Prior to
analysis, nuclei were stained with Hoechst 33342 (Sigma-
Aldrich).
Capillary-like tube formation assay
HUVECs were seeded at a density of 5 × 104 cells/well in the
EGM-2EV medium (Lonza) on 24-well plates coated with
Matrigel Matrix Grow Factor Reduced (BD Pharmingen;
100 μL/well, 30 min at RT). Fifty micrograms of EVs (har-
vested from approximately 6 × 106 cells) was added to select-
ed wells, and cells were incubated for 8 h at 37 °C. HUVECs
without EVs were used as a control. Tube formation was in-
vestigated every 2 h, and images were collected with a Leica
DMI6000B (ver. AF7000) equippedwith a CCD camera. Five
randomly selected images of high-power fields for cultured
cell groups in tested media at every experimental time point
were included in quantitative analysis and were computed as
the absolute number of capillary-like structures per experi-
mental group.
Inhibition of PBMC proliferation
PBMCs were stained with 25 μM carboxyfluorescein
succinimidyl ester (CFSE; Molecular Probes) for 15 min at
37 °C. Subsequently, the cells were stimulated with 50 ng/mL
of phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich)
and 1 ng/mL ionomycin (Sigma-Aldrich) for 24 h.
Unstimulated cells served as a control. After double washing
in PBS, 105 cells were seeded into 48-well plates in 200 μL of
RPMI (Sigma-Aldrich) supplementedwith 10% FBS (Sigma-
Aldrich) and P/S. Next, 100 μg of UC-MSC-EVs (harvested
from approximately 12 × 106 cells) was added per well and
cells were co-incubated with EVs for 4 days. Inhibition of
PBMC proliferation was measured on a BD LSRFortessa flow
cytometer (BD Biosciences) and was calculated as the decline
in the number of CFSE-positive cells using the FlowJo soft-
ware (FlowJo).
Statistical analysis
The experiments were performed using five UC-MSC
lines, at least twice in duplicate. The data is shown as
means ± standard deviations (SD). Statistical analyses
were done with one-way ANOVA and Dunnet’s post
hoc test. p values of less than 0.05 were considered sta-
tistically significant.
Results
Various xeno-free media differentially maintain
UC-MSCs characteristics
First, we investigated the influence of various xeno-free cul-
ture conditions on UC-MSCs properties. Thus, we compared
growth, phenotype, differentiation potential, metabolism, and
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longevity of UC-MSC cultured in xeno-free media to control
cells propagated in standard serum-based medium (with 10 %
FBS; M6) and serum-reduced medium (5 % FBS) supple-
mented with bFGF (5 ng/mL; M7), since bFGF has been
shown to enhance proliferation of UC-MSCs [27]. A scheme
of experimental procedures is shown in Fig. 1a.
We observed morphological differences between the
groups of cells (Fig. 1b). The spindle-like shape typical
for MSCs was preserved in media M1, M3, M5, and M6,
with the largest longitudinal axis in medium M7. In con-
trast, cells were more rounded in particular in medium
M2. Importantly, all the cells displayed the typical MSC
Fig. 1 Characterization of morphology, phenotype, and differentiation
potential of UC-MSCs cultured in various xeno-free media. a A time
schedule of the study. b UC-MSC morphology in xeno-free (M1, M2,
M3, M4, M5) and control media (M6 and M7) at passage 1.
Representative images in Nomarski Intereference Contrast are shown
with a scale bar of 100 μm. c Surface antigen expression on UC-MSCs
by flow cytometry. Cells were stainedwith selected antibodies conjugated
with fluorochromes, acquired on BD LSRFortessa (BD Biosciences) and
analyzed using the FlowJo software. Results are shown as a mean ± SD
for cells cultured in control medium M6. Representative histograms are
presented. d Differentiation potential of UC-MSCs into mesodermal
lineages. Representative images of UC-MSCs differentiated into
osteocytes, adipocytes and chondrocytes are shown as indicated (left).
Scale bar shows 100 μm. Calcium phosphate deposits were stained
with Alizarin Red-S, proteoglycans with Alcian Blue, and fat droplets
were visible in bright field. Mean percentage of differentiation of five
UC-MSCs lineages in all examined conditions (right). UC-MSCs
umbilical cord-derived mesenchymal stem cells
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phenotype with high expression of clusters of differentia-
tion markers including CD166, CD73, CD90, CD44,
CD105, and CD29 (Fig. 1c; Supplementary Table S2).
Simultaneously, the cells did not express hematopoietic
stem cell marker CD34, lineage commitment cell antigens
(CD45, CD14, CD16), and major histocompatibility class
II molecules (HLA-DR). Interestingly, the only difference
in phenotype was noticed for CD105 expression, which
was significantly downregulated in medium M5 and
lowered in medium M2 and M3 (Supplementary
Table S2).
Moreover, all the cells effectively differentiated into osteo-
cytes and chondrocytes; however, they displayed diminished
ability to differentiate into adipocytes with the exception of
cells cultured in medium M3 (Fig. 1d).
To extend characteristics beyond criteria established for
MSCs by the International Society for Cellular Therapy
(ISCT) [28], we also measured proliferation, metabolic, and
senescence rates of UC-MSCs cultured in different conditions.
The highest proliferation rate expressed as the shortest popu-
lation doubling time was observed for cells cultured in medi-
um M1 (Fig. 2a). Similarly, cells cultured in medium M1
displayed highest metabolic activity (Fig. 2b) and lowest se-
nescence rate compared to UC-MSCs propagated in other
tested conditions (Fig. 2c).
Immunomodulatory profile of UC-MSCs is affected
by cell culture conditions
Since UC-MSCs are known to exhibit the lowest immu-
nogenicity compared to MSCs from other sources and are
considered to be suitable for transplantation to unrelated
donors, we compared the secretion of pro- and anti-
inflammatory cytokines by cells cultured in different
xeno-free media. In parallel, we also compared transcript
levels for selected cytokines and for genes involved in
immunomodulation including GAL-3, JAG-1, NOTCH-2,
NOTCH-3, and regulators of apoptosis (BAX, BCL-2). The
results showed that UC-MSCs cultured in media M1, M2,
M4, and M5 produced lower levels of pro-inflammatory
cytokines including IL-1β, IL-8, IFNγ, and TNFα com-
pared to control medium M6 (Fig. 3a). In contrast, cells
cultured in medium M7 secreted these cytokines at the
highest levels, whereas medium M3 promoted cytokine
production at a similar level to control medium M6
(Fig. 3a). The media themselves did not input any back-
ground into the assay and did not contain any of the mea-
sured cytokines (data not shown). The concentrations of
the analyzed cytokines corresponded to their transcript
levels (Fig. 3b). A similar pattern of cytokine release by
UC-MSCs depending on the tested media was found for
other acute-phase mediators (Supplementary Fig. S1) as
well as for anti-inflammatory cytokines such as IL-6 and
IL-10 (Fig. 3c), including expression of their correspond-
ing mRNAs (Fig. 3d). Furthermore, real-time qPCR anal-
ysis revealed that the transcript level for GALECTIN-3
(GAL-3)—an important regulator of immune cell activa-
tion [29]—did not differ considerably among the tested
media (Fig. 3e). Interestingly, we found substantial differ-
ences in expression levels for genes related to the
NOTCH signaling pathway, with the lowest mRNA levels
for NOTCH-2 and NOTCH-3 and their ligand JAG-1 in
cells cultured in medium M3, whereas the highest
NOTCH-2 and NOTCH-3 expression was identified in
cells cultured in medium M2 (Fig. 3e). Furthermore,
genes involved in regulation of apoptosis were expressed
at similar levels among the different cell samples with the
exception of medium M4, in which the mRNA for anti-
Fig. 2 Proliferation potential, metabolic activity, and senescence rate of
UC-MSCs cultured in various xeno-free conditions. a Proliferation rate of
UC-MSCs measured after passages 1, 3, and 6 (P1, P3, P6) shown as
population doubling time (h). Cells (103) were seeded per well on 24-well
plates and after 3 days the number of cells was counted in a Buerker
chamber. b Metabolic activity of UC-MSCs. ATP concentration was
evaluated 24, 48, and 72 h after seeding of 103 cells/well on 96-well
plates, using the ATP Assay Kit (PerkinElmer). c Senescence of UC-
MSCs in prolonged culture. The assay was performed at passage 6 with
the Senescence β-Galactosidase Staining Kit (Cell Signaling
Technologies). A representative image of β-galactosidase-positive
(senescent) cells with a scale bar of 100 μm is shown (left). Mean
percentage of senescent cells in all examined media is shown on the
graph (right). Results are shown as means ± SD. Statistical differences
were measured with one-way ANOVA and Dunnet’s post hoc test
comparing all data to control conditions (M6). *p < 0.05. M1 to M7
correspond to the tested media. UC-MSCs umbilical cord-derived
mesenchymal stem cells
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apoptotic BCL-2 was identified in the highest quantity
(Fig. 3f).
EVs derived fromUC-MSCs cultured in various xeno-free
media display different characteristics
Supported by the growing body of evidence that paracrine
activity including cell-to-cell communication mediated by
EVs plays an essential role in MSCs-mediated tissue regener-
ation [10–16], we examined the size, content, and biological
properties of UC-MSC-EVs obtained from different condi-
tioned media. Following isolation, general characterization
of EVs was performed, according to the requirements of the
International Society for Extracellular Vesicles (ISEV) [30].
Nanoparticle tracking analysis (Fig. 4a) revealed that median
size of EVs collected in various xeno-free media was in a
range from 134.5 ± 13.4 to 145.5 ± 13.4 nm (Supplementary
Table S3) which was similar to the size of vesicles obtained in
the control medium M6 (138.5 ± 3.5), with exception of M4-
EVs, in which size was significantly smaller (127 ± 2.8). Next,
detection of proteins associated with EVs was analyzed by
western blot, indicating that all the collected EV specimens
exhibited presence of tetraspanin CD63, membrane associated
syntenin, although at variable levels (ISEV categories 1–2;
Fig. 3 Immunomodulatory profile of UC-MSCs cultured in various
xeno-free conditions. Secretion of a pro-inflammatory cytokines (IL-β,
IL-8, IFN-γ, TNF-α) and c anti-inflammatory (IL-6, IL-10) cytokines was
measured in conditioned media collected after passage 3 with the BioPlex
Pro™ Human Cytokine 17-plex Assay (BioRad). mRNA expression
levels of b pro-inflammatory cytokines, d ant-inflammatory cytokines,
e transcripts regulating immunomodulatory ligands and receptors (GAL-
3, JAG-1, NOTCH-2, NOTCH-3), and f apoptosis (BAX, BCL2) were
measured using the real time PCR and relative quantification with the
ΔΔCt method with β-2 microglobulin as endogenous control. Mean
values ± SD are shown. Results were compared with one-way ANOVA
and Dunnet’s post hoc test, relative to control conditions (M6). *p < 0.05.
M1 to M7 correspond to the tested media. UC-MSCs umbilical cord-
derived mesenchymal stem cells
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Fig. 4b; Supplementary Fig. S2). There was no expression of
an intracellular protein calnexin (ISEV category 3; data not
shown), as expected. Moreover, the vesicles also contained
transcripts for IL-8 (ISEV category 4; Fig. 4c) for which the
Fig. 4 Characteristic of EVs derived from UC-MSCs cultured in xeno-
free media (UC-MSC-EVs). a Size analysis of EVs using qNano system
(Izon Science Ltd). Representative image is shown. b Western blot
analysis of selected proteins in UC-MSC-EVs. Three hundred
micrograms of protein extracts was used to detect expression of
transmembrane (CD63) and cytosolic (syntenin) proteins. Expression of
β-actin was used as control. c Transcript level for extracellular protein
(IL-8) measured by RT-qPCR inUC-MSC-EVs. d Surface antigen profile
of UC-MSC-EVs by high-sensitivity flow cytometry. The EV samples
were stainedwith the SYTO®RNASelect™Green Fluorescent Cell Stain
(Molecular Probes) and selected antibodies labeled with a
fluorochrome and further analyzed on an A50-Micro Flow Cytometer
(Apogee Flow Systems). The percentage of particles positive for
indicated surface marker was analyzed from SYTO® RNASelect™-
positive objects (in gate R1). Representative dot plots for M1-EVs are
shown. e Analysis of transcript levels for genes involved in the
maintenance of pluripotency (NANOG) or differentiation toward cardiac
(GATA4) and endothelial lineage (FLK1) performed with the real time
PCR method in UC-MSC-EVs. f Relative transcript levels in EVs
compared to parental UC-MSCs. Results are shown as mean ± SD.
Results were compared with one-way ANOVA and Dunnet’s post hoc
test, relative to control conditions (M6). *p < 0.05. UC-MSC umbilical
cord-derived mesenchymal stem cells, UC-MSC-EVs extracellular
vesicles derived from UC-MSCs, M1 to M7 correspond to the tested
media. MALS medium angle light scatter, PS polystyrene calibration
beads, Si silicone calibration beads, FITC fluorescein isothiocyanate,
PE phycoerythrin, APC allophycocyanin
J Mol Med (2017) 95:205–220 213
highest expression was detected in case of M7-EVs.
Furthermore, expression of selected surface antigens was
measured on EVs using the Apogee A50-Micro flow
Cytometer, a novel high-resolution platform dedicated to anal-
ysis of nanoparticles. Knowing that EV cargo comprises pri-
marily RNAs, UC-MSC-EVs were stained with an RNA-
specific dye and only RNA-containing objects were consid-
ered in analysis. The results showed that approximately 15 to
19% of the collected particles were intact and contained RNA
(Fig. 4a; Supplementary Table S4). The highest RNA content
was detected in EVs derived from cells cultured in media M1
and M5 (Supplementary Table S4). Expression of surface
molecules typical for MSCs, including CD90, CD44, and
CD105, varied among different EV samples (Fig. 4d;
Supplementary Table S4) and was highest in case of EVs
harvested from media M1 and M3. Interestingly, the CD105
expression level was stable among EV samples despite differ-
ences observed in case of parental cells (Supplementary
Tables S2 and S4). Moreover, all the EV samples exhibited
integrin alpha-5 (CD49e; ISEV category 1; Fig. 4d); however,
its highest expression was measured onM2-EVs andM3-EVs
(Supplementary Table S4). The media did not generate back-
ground in the analysis since hardly any RNA-positive objects
were observed in the tested media (Supplementary Fig. S3).
In order to ascertain a potential role of UC-MSC-EVs in
tissue regeneration, particularly their cardiomyogenic and an-
giogenic potential, we analyzed mRNA content in EV speci-
mens for several genes related to these processes. The results
showed that all tested UC-MSC-EV samples contained tran-
scripts for NANOG, GATA4, and FLK1, although at variable
levels (Fig. 4e). Importantly, mRNA for GATA4 was enriched
in EVs compared to their parental cells (Fig. 4f). In contrast,
we failed to detect mRNA for other genes including NKX2–5
and TIE2 in most EV samples (data not shown), although they
were abundantly present in parental cells (Supplementary
Fig. S4).
Xeno-free UC-MSC-EVs enhance cardiomyogenic
and angiogenic potential of cardiac and endothelial cells
in vitro
To investigate potential impact of xeno-free UC-MSC-EVs on
differentiation properties of target cells including their
cardiomyogenic and angiogenic capacity required for heart
repair, we performed functional analyses of primary heart
and endothelial cells upon EVs treatment. Based on the pre-
vious data, we chose EVs derived from UC-MSCs cultured in
media M1, M3, and M4 as superior for maintenance of UC-
MSCs properties including proliferation rate (M1), metabolic
activity (M1), longevity (M1), differentiation potential (M3),
phenotype stability of the cells (M1, M4), and EVs (M1, M3),
as well as low level of cytokine production (M1, M4). The
biological influence of the selected types of EVs on target cells
was compared to control conditions (without EVs treatment)
and to the cell samples treated with control M6-EVs.
First, we studied the impact of the xeno-free EVs on pro-
liferation and cardiac differentiation of primary human cardiac
cells. Upon EVs treatment, the target cells were cultured either
in hypoxia (1 % O2) to mimic the conditions present in the
ischemic heart or at normal oxygen level (21 % O2) and after
4 days, cell number was assessed with a cell counting kit. A
significantly higher proliferation rate was observed for cMSCs
treated with all three types of xeno-free EVs (M1, M3, M4) in
hypoxic conditions. Moreover, EVs isolated from the condi-
tioned media M3 and M4 increased the proliferation of
cMSCs cultured in normoxia (Fig. 5a).
Cardiomyogenic differentiation of cMSCs was evaluated
after 7 days following EVs treatment, based on expression
levels of genes involved in cardiac development and presence
of intracellular cardiac markers. The real time PCR data indi-
cated elevated transcript levels particularly for transcription
factors GATA4 and NKX2–5 and to a lesser extent for cardiac
structural proteins—troponin TC (TnTC) and cardiac myosin
heavy chain B (MYCHCB) in cells treated with M3- or M4-
EVs (Fig. 5b). Results from the molecular analysis were fur-
ther confirmed by immunocytochemical detection of GATA4
and TnTC proteins in the target cells (Fig. 5c).
Next, to test the angiogenic potential of selected UC-MSC-
EVs, we investigated their impact on angiogenic capacity of
human endothelial cells by performing capillary-like tube for-
mation assay in vitro (Supplementary Fig. S5). Quantitative
analysis revealed a significant increase in the number of cap-
illaries formed by human endothelial cells co-incubated with
all four types of EVs (including control M6-EVs) at 6 h of the
experiment (Fig. 5d). This phenomenon was maintained for
M3 andM4-EV-treated samples at 8 h of the assay, resulting in
statistically higher number of capillaries compared to both
control untreated cells and cells treated with M6-EVs
(Fig. 5d). Representative images of capillary formation at ev-
ery indicated time point for cells treated and untreated with
EVs are shown in Fig. 5e.
MicroRNA content of EVs determines their
cardiomyogenic and angiogenic potential
We investigated the microRNA content of UC-MSC-EVs to
explain their observed pro-cardiomyogenic and pro-
angiogenic activity. Expression of selected miRNAs was
screened in M3- and M4-EVs, which showed the most prom-
inent stimulatory effects in both cMSCs and human endothe-
lial cells, and was compared to the miRNA content in control
M6-EVs.
The analysis revealed that UC-MSC-EVs contained
various miRNAs crucial for cardiac and angiogenic cell
differentiation (Fig. 5f, g). We identified significantly
greater concentration of several miRNAs with pro-
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cardiomyogenic and cardioprotective role including
miR199a-3p, miR-199a-5p [31], and miR-23a-3p [32] in
M3- and M4-EVs and elevated level of miR-24a [33] in
M3-EVs when compared to the control M6-EVs (Fig. 5f).
Interestingly, other pro-cardiomyogenic miR-19b-3p [31]
was detected at a higher level in M6-EVs (Fig. 5f).
Notably, miR-16-5p which was shown to exhibit inhibito-
ry effects on cardiomyocyte proliferation and differentia-
tion [31] was at the same time enriched in M6-EVs
(Fig. 5f). With respect to pro-angiogenic miRNAs, the
analysis revealed that particularly M3-EVs contained sig-
nificantly elevated levels of miR-132-3p, miR-21-5p, and
miRNAs belonging to the let-7 family (let-7a-5p, let-7b-
5p, and let-7f-5p) [34] compared to control (Fig. 5g). On
the contrary, M6-EVs showed the highest level of miR-
126 expression, one of the key regulators in angiogenesis
[34] (Fig. 5g).
UC-MSC-EVs from distinct xeno-free media possess
different immunoregulatory capacity
Considering possible future clinical applications of xeno-free
UC-MSC-derived EVs and their immunomodulatory proper-
ties, we performed an in vitro analysis of EVs impact on
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human immune cell activation. Thus, we examined prolifera-
tion status of mitogen-activated peripheral blood mononuclear
cells in response to the treatment with EVs. Selected EV spec-
imens were co-incubated with CFSE-labeled PBMCs for
4 days, and changes in CFSE-positive fraction were measured
by flow cytometry. Surprisingly, the obtained data indicated
distinct response of PBMCs to contact with EVs isolated from
different xeno-free media. Both inhibition and stimulation of
PBMCs were observed depending on the type of EVs and the
initial proliferation status of the immune cells (Fig. 6). The
most pronounced inhibitory effect was noticed for M3-EVs,
whereas the highest rate of stimulation was observed for M4-
EVs (Fig. 6a). In case of M1-EVs, the immune cells exhibited
mainly no response following the treatment with EVs. The
decrease or increase of PBMCs proliferation varied among
the tested cell samples from 0 to 60 % (Fig. 6b). Moreover,
proliferation rate of PBMCs in response to the stimulation
with mitogens (PMA and ionomycin) differed among individ-
ual cell donors indicating two groups identified as Bgood
responders^ and Bpoor responders.^ Stronger inhibition of
proliferation mediated by UC-MSC-EVs was observed in
the case of good responders for which the degree of prolifer-
ation was higher than 60 % (Fig. 6c). On the contrary, PBMC
donors with the status of poor responders reacted to the treat-
ment with UC-MSC-EVs either with stimulation or inhibition
of proliferation (Fig. 6d).
Discussion
Several attempts have already been made to analyze the influ-
ence of xeno-free cell culture conditions on the properties of
MSCs. Growing evidence indicate similar or superior prolif-
erative capacity as well as maintenance of three-lineage dif-
ferentiation ability and surface antigen expression of MSCs
cultured in xeno-free media compared to standard serum-
based conditions [18–21], which was further supported by
our results. However, the potential impact of such xeno-free
media on the properties of MSC-EVs has not been studied.
We hypothesized that similarly to the changes triggered in
cells, variable cell culture conditions may alter biological car-
go within MSC-EVs, thereby promoting their specific proper-
ties. Thus, we investigated differences in characteristic of UC-
MSCs cultured in various xeno-free media, as well as in ther-
apeutic properties of extracellular vesicles derived from these
cells in the context of their potential use in regenerative med-
icine. We particularly focused on pro-cardiomyogenic and
pro-angiogenic properties of the UC-MSC-EVs, as well as
their immunomodulatory function, which all may contribute
to the repair of injured heart tissue [1, 35]. To address these
points, we performed a comprehensive analysis of morpho-
logical, functional, and molecular features of the parental UC-
MSCs and their EVs released in different culture conditions.
We provide, for the first time, a versatile survey on xeno-free
UC-MSC-EVs, with the goal to employ these data in potential
clinical applications in the future.
We demonstrated that cellular properties typical for MSCs
including proliferation rate, metabolism, longevity, differenti-
ation potential, and phenotype stability varied in different
xeno-free media (Fig. 7, upper part). In particular, we ob-
served that the xeno-free medium M1 was the most effective
in promoting UC-MSCs proliferation, metabolic activity, and
preserving their longevity, whereas medium M3 ensured
three-lineage differentiation potential. Furthermore, the sur-
face antigen profile was maintained in the xeno-free media
M1 and M4.
Similarly to the influence on cellular characteristics of UC-
MSCs, variable cell culture conditions impacted the charac-
teristic and biological effects exerted by UC-MSC-EVs on
target cells (Fig. 7, lower part).
In particular, medium M4 promoted secretion of EVs by
UC-MSC with smallest size. Notably, M2-EVs and M5-EVs
contained the membrane-bound protein syntenin at the lowest
level. Similarly, expression of a cytokine, IL-8 differed among
the tested samples, and its highest level was detected for M7-
EVs.
Additionally, our data on cardiomyogenic activity of UC-
MSC-EVs revealed that certain populations of the xeno-free
EVs (M3-EVs, M4-EVs) significantly enhanced the cardiac
differentiation ability of human primary heart cells in vitro.
We speculate that this effect might have been triggered by
Fig. 5 Cardiomyogenic and angiogenic potential of xeno-free UC-MCS-
EVs in vitro. a Proliferation of cMSCs treated with UC-MSC-EVs (1 μg/
103 cells) and cultured 4 days in normal (21 % O2) or hypoxic (1 % O2)
conditions, measured with the Cell Counting Kit-8 (Sigma-Aldrich). b
Transcript level analysis in cMSCs treated with UC-MSC-EVs (50 μg/
5 × 104 cells) and subjected to cardiac differentiation for 7 days.
Expression of mRNA was measured using the real time PCR and
comparative ΔΔCt analysis with β-2 microglobulin as endogenous
control. c Immunocytochemical staining of cMSCs upon cardiac
differentiation for 7 days. Upper panel: undifferentiated control; middle
panel: differentiated control (cMSC without treatment with UC-MSC-
EVs); bottom panel: cells differentiated after treatment with UC-MSC-
EVs. d Capillary formation by human endothelial cells (HUVECs)
treated with UC-MSC-EVs (50 μg/5 × 104 cells). Number of capillaries
was counted every 2 h during 8-h experiments in five randomly selected
microscopic fields. e Microscopic pictures of capillaries formed by
HUVECs untreated (upper panel) or treated with UC-MSC-EVs (lower
panel) at indicated time points. f Detection of pro-cardiomyogenic
miRNAs in UC-MSC-EVs. g Detection of pro-angiogenic miRNAs in
UC-MSC-EVs. Representative images are shown for microscopic data.
Scale bars indicate 100 μm. For graphical charts: results are shown as
mean ± SD. Significant differences in values obtained for cells treated
with UC-MSC-EVs and untreated differentiated control (#p < 0.05), as
well as between xeno-free and control media (M6 shown as a red column,
*p < 0.05) were evaluated by ANOVA. For miRNA analysis: samples
statistically enriched or underexpressed (p < 0.05) compared to control
M6-EVs are indicated with an asterisk or an inverted triangle,
respectively. UC-MSC-EVs extracellular vesicles derived from umbilical
cord mesenchymal stem cells, cMSCs cardiacmesenchymal stromal cells,
HUVECs human umbilical vein endothelial cells, Cto control, Cto diff.
differentiated control, BF bright field (color figure online)
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RNA molecules contained in the EVs, since elevated transcript
levels for pro-cardiomyogenic gene GATA4, as well as for cer-
tain cardiac regulatory miRNAs (miR-23a-3p, miR-24a-3p,
miR-199a-3p/5p) [31–34] were detected in UC-MSC-EVs.
These results are in line with data presented by Yu B et al.,
who showed that exosomes derived fromGATA-4 overexpress-
ing ratMSCs exerted a cardioprotective role on infarcted hearts,
mainly by the activity of several cytoprotective miRNAs [36].
Importantly, MSC-EVs were already demonstrated to pos-
sess pro-angiogenic activity in vitro and in vivo [37–39].
However, differences in this potential resulting from the type
of cell culture media have not been investigated so far. Our
functional assay performed on human endothelial cells indicat-
ed that certain populations of the xeno-free UC-MSC-EVs (in
particular M3-EVs and M4-EVs) stimulated formation of
capillary-like structures in vitromore efficiently than the control
M6-EVs. Thus, we speculate that application of M3-EVs or
M4-EVs into an ischemic tissue may result in increased vascu-
larization. Moreover, we found several miRNAs of known pro-
angiogenic activity, including miR-132-3p, miR-21-5p, and the
members of let-7 family [34], to be enriched in the xeno-free
EVs compared to the control M6-EVs. On the contrary, there
was no major difference in the presence of several surface re-
ceptors in the membrane compartment of these EV specimens.
These results suggest that the cytoplasmic cargo rather than
surface molecules defines the biological potential of the EVs.
Another important aspect of the potential utility of UC-
MSC-EVs in clinical applications involves the immune re-
sponse of a host toward transplanted material. It has been well
documented that MSCs exert an immunosuppressive effect on
Fig. 6 UC-MSC-EVs impact on proliferation of peripheral blood
mononuclear cells (PBMCs). PBMCs were stained with 25 μM CFSE
(Molecular Probes) and stimulated with 50 ng/mL PMA and 1 ng/mL
ionomycin (both from Sigma-Aldrich) for 24 h. Next, cells were treated
with 100 μg of UC-MSC-EVs for 4 days, and decline in CFSE-positive
cells was measured by flow cytometry. a Summary of observed effects
exerted by UC-MSC-EVs on PBMCs. Percentage of stimulation,
inhibition, or no effect measured in five experiments with the use of
four UC-MSC-EV types are shown. b Effects of single UC-MSC-EV
samples on proliferation of PBMCs. Every measurement is indicated as
a black dot, mean values are shown as horizontal lines. c Inhibition of
PBMCs proliferation by two UC-MSC-EV specimens in a sample of a
Bgood responder^ to PMA/ionomycin stimulation (>80 % of PBMCs
proliferation). Representative histograms are shown. d Dual effect of
UC-MSC-EVs on PBMCs proliferation, either stimulation or inhibition,
in a sample of a Bpoor responder^ to PMA/ionomycin stimulation (<40%
of PBMCs proliferation). UC-MSC-EVs extracellular vesicles derived
from umbilical cord mesenchymal stem cells, PBMCs peripheral blood
mononuclear cells, CFSE carboxyfluorescein succinimidyl ester, PMA
phorbol 12-myristate 13-acetate
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various populations of immune cells, including T- and B-lym-
phocytes, natural killer cells, and dendritic cells [40]. Among
MSCs isolated from different sources, UC-MSCs are believed
to be the least immunogenic [41]. The immunomodulatory
activity of MSCs is attributed to the secretion of certain me-
diators including IL-6, IL-10, prostaglandin E2 (PGE2), HGF,
indoleamine 2,3-dioxygenase (IDO), nitric oxide (NO) TGF-
b1, human leukocyte antigen G (HLA-G), and recently appre-
ciated extracellular vesicles [40].
With respect to the immunomodulatory function of MSC-
EVs, the literature shows contradictory results. Bone marrow
or adipose tissue MSC-EVs were demonstrated to posses im-
paired ability to suppress lymphocyte proliferation, in contrast
to their cellular counterparts [42, 43]. On the other hand,
Zhang et al. provided evidence that exosomes secreted by
human embryonic stem cell (ESC)-derived MSCs are immu-
nologically active [44]. Despite the differences related to the
source of parental MSCs, our data indicate that certain popu-
lations of MSC-EVs collected from individual donors may
exert inhibitory or stimulatory effects on immune cells, de-
pending on the type of medium used for culture of parental
MSCs. In our experimental setting, M3-EVs were particularly
potent inhibitors of proliferating PBMCs, in contrast to M1-
EVs andM4-EVs. To explain the observed results, we provide
molecular evidence of immunosuppressive character of the
respective parental cells. First, we detected IL-6, suggested
as a surrogate of immunosuppressive effects of stem cells
[45], secreted at a high level by MSCs cultured in the medium
M3 compared to other xeno-free media. Second, we found
that these cells also secreted IL-10, a regulator of T-cells and
a suppressor of the inflammatory immune response [46].
Furthermore, we detected a high level of expression of
Galectin-3, which has been proposed as a biomarker for the
immunomodulatory properties of UC-MSCs [47], although a
similar expression pattern was found among all tested MSC
populations. On the contrary, transcripts related to the
NOTCH signaling pathway implicated in immune regulation
by MSCs [48, 49] were present at variable levels in the tested
UC-MSC samples. Surprisingly, NOTCH-2 and NOTCH-3
and the ligand Jagged-1 were expressed at the lowest level
by MSCs cultured in the medium M3, which suggests that an
unknown mechanism was involved in promoting the immu-
nosuppressive character of M3-EVs, which is in need of fur-
ther exploration.
In summary, data obtained in this work implicate beneficial
e f f e c t s o f ce r t a i n xeno - f r e e UC-MSC-EVs on
cardiomyogenesis, angiogenesis, and immunomodulation
and also highlight the importance of circumspect selection of
the type of media for EVs collection to promote their specific
required characteristics. In particular, we found that prolifera-
tion and cardiac differentiation of human cardiac cells as well
as capillary formation by endothelial cells were stimulated to
the highest degree by EVs obtained from media M3 and M4.
However, the inhibition of mitogen-stimulated PBMCs was
most achieved after treatment with M3-EVs, whereas the op-
posite effect was observed in the presence ofM4-EVs (Fig. 7).
Moreover, growing evidence from incoming studies brings
us closer to novel cell-free therapies with stem cell-derived
specimens that may be utilized in tissue repair and other treat-
ments in humans. Recently, the first report of successful use of
MSC-EVs in the treatment of graft-versus-host disease in a
human patient was published [50]. Such data make the idea of
Fig. 7 Summary of observed
impact of various xeno-free
media on UC-MSC and EV
properties. Upper arm: impact of
distinct xeno-free media on
proliferation rate, metabolic
activity, longevity, differentiation
potential and phenotype stability
of UC-MSCs. Lower arm:
functional properties of EVs
derived from UC-MSCs (UC-
MSC-EVs) in different xeno-free
media and their impact on (i)
proliferation and differentiation
capacity of primary cardiac cells,
(ii) angiogenic capacity of
endothelial cells, and (iii)
proliferation of immune cells.
Green arrow indicates
stimulation/enhancement of the
indicated process, while the red
arrow shows inhibition (color
figure online)
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potential applications of extracellular vesicles in regenerative
medicine more appealing and bring it closer to the clinical
trials in the near future. Results from our study further support
this concept showing a novel, effective cell-free treatment
option, which may be customized for certain applications by
selecting an appropriate xeno-free cell culture system for UC-
MSCs propagation and EVs collection.
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